Compare iShares MSCI United Kingdom (FTSE) (EWU) vs Heron Therapeutics Inc (HRTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares MSCI United Kingdom (FTSE) vs Heron Therapeutics Inc — how do they compare? iShares MSCI United Kingdom (FTSE) trades at $46.35 (market cap $3.62B), while Heron Therapeutics Inc trades at $0.39 (market cap $68.01M). The key difference: iShares MSCI United Kingdom (FTSE) is far larger — about 53.2× Heron Therapeutics Inc's market cap, and iShares MSCI United Kingdom (FTSE) is trading nearer its 52-week high, Heron Therapeutics Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold iShares MSCI United Kingdom (FTSE) for 46 Days and Heron Therapeutics Inc for 35 Days on average.
| EWU | HRTX | |
|---|---|---|
Market Cap | $3.62B | $68.01M |
Volume | 923,896 | 1,891,941 |
Sector | Broad Market / Factor | Health |
52-Week High | $49.39 | $1.49 |
52-Week Low | $41.34 | $0.27 |
Typical Hold Time | 46 Days | 35 Days |
Enterprise Value | — | $174.75M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
EWU, the iShares MSCI United Kingdom ETF, is trading at $45.93, down 0.95% amid broader market pressures. Technical indicators show a bearish trend with moving averages signaling sell pressure, though RSI levels suggest potential oversold conditions. The fund faces headwinds from UK economic concerns including rising gilt yields and inflation pressures, while recent government housing initiatives provide some sector-specific support.
The outlook remains cautious as UK economic vulnerabilities and rising borrowing costs weigh on sentiment. Investment opportunity exists for long-term investors seeking UK exposure at discounted levels, though near-term risks include persistent inflation and political uncertainty surrounding the upcoming budget announcement.
Heron Therapeutics (HRTX) trades at $0.39, up 0.95% with a bullish technical signal from moving averages. The company reported Q2 2026 revenue of $37.7M but missed EPS estimates with a $0.03 loss. Despite negative profitability metrics, analyst consensus remains strongly positive with 89% buy ratings. Recent news highlights ongoing comparisons with peers and earnings discussions.
The outlook remains challenged by persistent losses and negative margins, though strong analyst support suggests potential upside. Key risks include execution on sales targets and achieving profitability. The stock's low price near 52-week lows presents speculative opportunity but requires careful risk management given financial performance.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About iShares MSCI United Kingdom (FTSE)
EWU is a country-specific ETF that tracks the performance of the United Kingdom equity market. It provides exposure to large and mid-sized UK companies, with significant weightings in financials, energy, and healthcare, including Shell, AstraZeneca, and HSBC.
Read more on EWU →About Heron Therapeutics Inc
Heron Therapeutics is a commercial-stage biotechnology company focused on improving patient care. It develops best-in-class medicines for pain management and cancer care to address unmet medical needs.
Read more on HRTX →
